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Abstract
Most AIDS-associated non-Hodgkin’slymphoma(AIDS-NHL)arisesfrom errors inimmunoglobulin heavy-chain gene (IgH)class
switch recombination (CSR) or somatic hypermutation (SHM), events that occur in germinal center (GC) B cells and require the
activity of activation induced cytidine deaminase (AID). Several oncogenic viruses (EBV, HCV, HPV) can induce AID gene (AID)
expression, and elevated AID expression is seen in circulating lymphocytes prior to AIDS-NHL diagnosis. Here, we report that
HIV produced in peripheral blood mononuclear cells (PBMC) induced AID expression in normal human B cells. Since HIV
produced in PBMC contains host cell CD40 ligand (CD40L) incorporated into the viral membrane, and CD40L is known to
induce AID expression in human B cells,the role of virion-associated CD40L in HIV-induced AID expression was examined. Only
viruses expressing functional CD40L were seen to induce AID expression; CD40L-negative HIV did not induce AID expression.
The induction of AID expression by CD40L+ HIV was abrogated by addition of blocking anti-CD40L antibody. AID protein was
detected in B cells exposed to CD40L+ HIV using intracellular multicolor flow cytometry, with most AID producing B cells
expressing the CD71 activation marker on their surface. Therefore, HIV virions that express CD40L induce AID expression in B
cells, and this induction appears to be due to a direct interaction between CD40L on these viruses and CD40 on B cells. These
findings are consistent with a role for HIV in the direct stimulation of B cells, potentially leading to the accumulation of
molecular lesions that have the potential to contribute to the development of NHL.
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Introduction
It has been known for some time that HIV infection is
associated with chronic B cell hyperactivation [1,2,3,4], and also
that levels of several cytokines and immune system molecules
associated with B cell activation are elevated prior to the
development of AIDS-NHL [5,6,7,8,9,10]. The activation of B
cells can result in the expression of activation-induced cytidine
deaminase (AID), a DNA-mutating enzyme that plays a central
role in two DNA-modifying activities normally seen to follow B
cell activation: immunoglobulin heavy chain gene (IgH) class-
switch recombination (CSR) and somatic hypermutation (SHM)
[11]. The expression of the AID gene (AID) also has been seen to
be associated with the mutation and/or translocation of
oncogenes associated with NHL; therefore, AID expression and
activity is thought to play a seminal role in the genesis of B cell
NHL [12].
AIDS-associated non-Hodgkin’s lymphoma (AIDS-NHL) is a
common cancer in HIV infected (HIV+) subjects [13]. In fact,
NHL is the most common AIDS-related cancer in HIV+
populations that have access to effective anti-retroviral treatment
[14,15]. While virtually all AIDS-NHL are B cell tumors, these
tumors are heterogeneous, representing different types of NHL,
which differ mainly in terms of molecular lesions, as well as in
infection of tumor cells with oncogenic viruses. AIDS-NHL are
thought to arise from: 1) loss of immunoregulatory control of
Epstein-Barr Virus (EBV) infection of B cells, and/or 2) chronic
immune activation of B cells, associated with immune system
dysfunction caused by HIV infection, and resulting in the
accumulation of oncogenic molecular lesions [16]. Therefore,
both uncontrolled viral infection and B cell activation-associated
DNA damage can promote the development of AIDS-NHL.
In recent work, we showed that AID is elevated prior to AIDS-
NHL diagnosis, in some cases over a period of several years [17].
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11448Infection of B cells by EBV can result in the transformation of such
cells, potentially resulting in EBV+ lymphomas in the setting of
severe immune deficiency. However, EBV and other viruses,
including hepatitis C virus (HCV), also can induce AID expression
and oncogene mutation, providing another means by which
oncogenic viruses could contribute to lymphomagenesis [18]
[19,20]. Little is known about the mechanism(s) involved in the
direct induction of AID expression by oncogenic viruses.
It has been thought that the contribution of HIV infection to the
development of AIDS-NHL is due to indirect effects, such as the
loss of T cells responsible for controlling infection with oncogenic
viruses, or by the HIV-driven overproduction of B cell stimulatory
factors such as cytokines [7] or ferritin [21], rather than mediated
via a direct interaction between HIV virions and B cells. However,
there is evidence that HIV itself can directly induce polyclonal B
cell activation. Schnittman and co-workers reported that HIV
could directly induce B cell activation more than twenty years ago
[22]. More recently, it has been reported that HIV can directly
induce B cell activation, via either gp120:DC-SIGN interactions
[23], or via the stimulation of CD40+ B cells by CD40 ligand
(CD40L) incorporated into HIV virions [24], or perhaps via
interactions with Toll-like receptors (TLR) [25]. Therefore, it
appears that direct HIV:B cell interactions can result in the
activation of these cells, which has the potential to contribute to
the generation of molecular errors that result in the development
of B cell lymphoma. This possibility led us to examine directly the
potential for HIV to induce AID expression in human B cells. It
was seen that exposure of B cells to HIV led to AID expression,
and that this did not require infection of B cells. Additionally, it
was seen that HIV virion-associated CD40L (CD154) was
responsible for the induction of AID expression in human B cells.
Results
Exposure of human B cells to HIV results in the induction
of AID expression
B cells were purified from PBMC isolated from healthy donors,
exposed to HIVNL4-3 for 2 hours, and then kept in culture for 3
days. Following this, AID expression was measured by RT-PCR or
Taqman RT-PCR. As a positive control for AID expression, we
used the Ramos cell line, and as a negative control we used the
monocytic cell line THP-1, which does not express AID. When
circulating B cells were exposed to HIVNL4-3 virions produced in
PBMC, we observed induction of AID mRNA expression
(Figure 1). In contrast, when B cells were exposed to mock
supernatant, produced from uninfected PBMC, AID expression
was not induced. When B cells were exposed to anti-CD40 and IL-
4 as a positive control, AID expression was also seen to be induced
at high levels. The Taqman RT-PCR assay used in this study was
developed specifically to detect only active AID and not an AID
splice variant (AIDvar) that is expressed in unstimulated circulating
B cells [17,20]. We observed that B cells exposed to HIVNL4-3
expressed AID, at a level approximately 35% of that seen in B cells
stimulated with agonistic anti-CD40+IL-4, which was used as a
positive control (Figure 1).
There was no change in p24 expression after B cells were
exposed to HIVNL4-3 (data not shown), making it unlikely that
HIV infection of B cells is necessary for AID expression, since viral
replication did not appear to occur in these cultures.
NL4-3 and JR-CSF viruses incorporate CD40L
It has been shown by others [24,26] that CD40L can be
incorporated into HIV’s viral envelope membrane upon viral
budding from infected cells. Since direct HIV infection of B cells
did not occur, this appeared unlikely to be responsible for the
observed AID induction following exposure of B cells to HIV.
Given that stimulation of B cells by CD40L is known to potently
induce AID expression, we considered the possibility that the
interaction between HIV virion-associated CD40L and CD40 on
B cells was responsible for the induction of AID expression seen
upon exposure to HIV.
In order to determine if HIV virion-associated CD40L has the
capability to induce AID expression in circulating B cells, we
produced HIV virions that contained CD40L, as well as HIV that
was CD40L-negative. To do this, we transfected 293T cell line
with CD40L or CD40Lmut (T147N) plasmids, along with HIVNL4-3
Figure 1. HIV induces AID expression. Taqman RT-PCR was performed used to quantify AID and GAPDH expression in: the monocytic cell line
THP-1 (THP-1), Ramos cell line (Ramos), or B cells that were exposed to mock (MOCK) or HIV-containing supernatant (HIV) for 3 days, or treated with
anti-CD40 and IL-4 (anti-CD40+IL-4) (positive control) for 3 days. n.d: non-detectable.
doi:10.1371/journal.pone.0011448.g001
AID Induced by CD40L+ HIV
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patients with hyper-IgM syndrome; this CD40L mutant is
recognized by CD40L antibodies but does not effectively stimulate
B cells via interactions with CD40. It was confirmed by flow
cytometry that 293T cells did not express membrane CD40L (data
not shown). However, when 293T cells were transfected with
CD40L or CD40Lmut, surface membrane expression of CD40L
was detectable (not shown). In order to confirm that these viruses
did, or did not express CD40L or CD40Lmut, we purified the
viruses with magnetic beads coated with anti-CD40L, and then
measured p24 expression by ELISA. Viruses grown in 293T cells
that were co-transfected with, and expressed, CD40L or mutant
CD40L, were seen to bind to CD40L antibody-bound beads
(Figure 2), confirming that these HIV virions did express CD40L.
We also confirmed the presence of CD40L in virions grown in
activated-PBMC (Figure 2a), as it had been previously reported
that both NL4-3 and JR-CSF incorporated CD40L when
produced in such cells in vitro [26]. Additionally, we isolated
CD40L-positive HIV from the plasma of HIV+ subjects,
confirming that incorporation of CD40L into HIV virions also
occurs in vivo (Figure 2c).
NL4-3 and JR-CSF viruses that are CD40L+ induce AID
expression in B cells
After confirming that HIV produced in 293T cells expresses
CD40L upon co-transfection with CD40L (or mutant CD40L), we
exposed purified circulating B cells to these different viral
preparations. It was seen that the HIV virions (NL4-3 or JR-
CSF) produced in 293T cells co-transfected with HIV and CD40L
were able to induce AID expression in B cells (Figure 3). On the
other hand, the virions that expressed either CD40Lmut (which
does not stimulate B cells), or did not express CD40L (virions
produced in cells that were not co-transfected with CD40L), were
not able to induce AID expression in B cells, suggesting that HIV is
stimulating B cells in a direct manner via virion-associated CD40L
interaction. B cells were also exposed to supernatants from 293T
cells, or 293T cells that were transfected with either CD40L or
CD40L mutant, but not with HIV. None of these preparations
induced AID expression in B cells.
Addition of a blocking antibody to CD40L resulted in the
abrogation of AID expression induced by CD40L-positive HIV
preparations (Figure 3), confirming that the induction of AID
expression in B cells is due to the CD40L:CD40 interaction.
Treating the B cells with this blocking anti-CD40L antibody,
without added virus, did not appear to have any effect on AID
expression in B cells. It is also interesting to note that both X4 and
R5 viruses were seen to have the ability to incorporate CD40L and
to induce AID expression in B cells (Figure 3).
We wanted to confirm that HIV infection of B cells was not
required for B cell activation and induction of AID expression, so B
cells were exposed to HIV virions containing CD40L, and
simultaneously exposed to zidovudine (AZT), to prevent viral
replication. In the presence of AZT, AID expression was still seen
in CD40L+ virion-exposed B cells, confirming that viral
replication does not appear to be required for the induction of
AID expression by these CD40L+ HIV preparations (data not
shown).
CD40L positive HIV virions induce AID protein expression
in B cells
We wanted to determine if the induction of AID gene
expression following exposure of B cells to CD40L+ HIV resulted
not only in elevated levels of AID mRNA, but also in elevated
levels of AID protein. For this purpose we measured AID protein
expression by intracellular multi-color flow cytometry in B cells
that had been exposed to CD40L positive or CD40Lmut (T147N)
NL4-3 HIV preparations, grown in CD40L(+) or T147N(+) 293T
cells. AID protein was seen in B cells exposed to CD40L-positive
HIVNL4-3, as well as in B cells stimulated with anti-CD40+IL-4:
2.1160.55 (SD)% of CD19+ cells exposed to CD40L+ HIVNL4-3
for three days expressed intracellular AID, while 0.2560.13% of B
cells exposed to CD40Lmut+ HIVNL4-3 and 0.1760.13% of B
cells exposed to mock supernatants were AID+ (P,0.02, t test
comparing CD40L+ HIVNL4-3 to mock supernatant negative
control). There was no significant increase in AID protein
expression detected in cells exposed to mock preparations (virus
negative) or to HIVNL4-3 incorporating mutant CD40L (Figure 4).
To determine if these AID positive B cells displayed other markers
of B cell activation, multi-color flow cytometry was performed for
intracellular AID, and cell surface CD19, CD10 and CD71.
CD71, the transferrin receptor, is an activation marker for human
B cells. It has been seen by others that the majority of AID-positive
GC B cells also co-express CD71 [27]. Additionally, in a prior
study we found that elevated levels of CD71+ and CD10+ B cells
were seen in the circulation of persons with HIV infection and
AIDS [3]. We observed exposure of human B cells to CD40L-
positive HIV (or to anti-CD40+IL-4) led to a significant increase in
CD71 expression on these cells: 2662.8% of CD19+ cells exposed
to CD40L+ HIVNL4-3 expressed CD71 on their surface, while
2.261.1% of B cells exposed to CD40Lmut HIVNL4-3 and
1.761.3% of B cells exposed to mock supernatants were CD71+
(P,0.004, t test comparing CD40L+ HIVNL4-3 to mock
supernatant negative control). The majority of B cells that
expressed AID following exposure to CD40L-positive HIV also
expressed CD71: 9464.4% of AID+ B cells exposed to CD40L-
positive HIVNL4-3 supernatants co-expressed CD71. Additionally,
1966.8% of the AID+ B cells seen following exposure to CD40L-
positive HIV also co-expressed CD10, a marker for immature and
GC B cells [3,27,28]. Together, this suggests that the AID
expression induced in B cells following exposure to CD40L-
positive HIV occurs in cells that have been induced to express an
activated/GC phenotype.
CD40L positive HIV virions induce cytokine secretion by
virus-exposed B cells
Cytokine expression was also measured in the supernatants of B
cells that were exposed to CD40L+ virions, as well as positive and
negative control stimuli, in two independent experiments. IL-2,
IL-10, GM-CSF, IL-6 and IL-8 were all elevated in B cells
exposed to CD40L+ HIV preparations when compared to controls
(Figure S1).
Discussion
Defects in B cell immunity and chronic B cell activation have
been recognized as features of HIV infection and AIDS for some
time [1,2,3,4]. However, the role of direct interactions between
HIV and B cells in this process has been less clear. Early reports
indicated that HIV could directly stimulate B cell activation [22],
but for the most part, B cell activation in the setting of HIV
infection has been thought to be due to HIV disease-associated
immune dysfunction, such as loss of immunoregulatory T cell
control of EBV infected B cells, response to HIV antigens [29],
superantigen stimulation of B cells [30], and/or the overproduc-
tion of inflammatory and B cell-stimulatory cytokines [31,32,33]
[34]. However, more recently, some reports have indicated that
HIV may be able to induce B cell activation directly. For instance,
AID Induced by CD40L+ HIV
PLoS ONE | www.plosone.org 3 July 2010 | Volume 5 | Issue 7 | e11448Figure 2. HIV virion-associated CD40L. Viruses (NL4-3 (A) or JR-CSF (B)) were grown in 293T cells (293T), 293T cells that expressed CD40L (CD40L
293T), 293T cells that expressed non-functional mutant CD40L (CD40Lmut 293T), or PBMC (PBMC), then CD40L expressing viruses were purified using
magnetic beads coated with anti-CD40L, followed by assessment of HIV content by quantification of HIV p24 levels by ELISA. Black bars represent
virions (NL4-3 or JR-CSF) not bound to beads, which are therefore CD40L-negative virions, (CD40L(2)) and white bars represent virions (NL4-3 or JR-
CSF) bound to beads, which are therefore CD40L-positive virions (CD40(+)). C) Plasma from HIV-seropositive subjects was incubated with magnetic
AID Induced by CD40L+ HIV
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gp120 was interacting with receptors on B cells, including DC-
SIGN, leading to B cell activation (class switch recombination, AID
expression and interleukin secretion). Other reports, by Martin
and co-workers [35] [26], concluded that CD40L, an immune
stimulatory molecule expressed by activated T cells, is incorpo-
rated into HIV virions and can stimulate B cells via CD40L:CD40
interactions. However, the effect of virion-incorporated CD40L on
AID expression was not examined in that study. These recent
reports defined molecular interactions that might play a role in the
direct activation of B cells by HIV.
Here we confirm that HIV does indeed appear to interact
directly with B cells through the interaction of CD40L with CD40,
and report that this interaction results in the induction of AID
gene and protein expression in resting human B cells, isolated from
the PBMC of HIV-negative donors. Elevated cytokine secretion,
as well as expression of CD71, a marker of cellular activation, also
was seen in B cells stimulated by exposure to CD40L-containing
HIV, with most AID expressing cells also co-expressing CD71.
Additionally, many AID expressing cells were CD10 positive. This
indicates that these HIV-stimulated AID expressing B cells have
an activated/GC phenotype.
These findings are notable, as AID is a DNA-modifying enzyme
that is believed to play a central role in the development of B cell
NHL. Since AID is a central effector in both IgH CSR and SHM
[11,12], and errors (oncogene translocation and/or mutation) in
these processes lead to the development of NHL, the induction of
AID expression has the potential to play a seminal role in the
genesis of these cancers. We also found that plasma HIV from
some HIV+ subjects was CD40L-positive, indicating that the
incorporation of CD40L into virions also occurs in vivo. Because of
this, the B cell activation observed in these studies has the potential
to also occur in vivo. Further studies are needed to show if HIV-
associated host cell immune stimulatory molecules are involved in
the induction of AID expression in vivo.
The observation that HIV virions can interact directly with
resting human B cells to induce AID expression, without the
requirement for infection, and via the interaction of virion-
associated CD40L with CD40 on B cells, provides a direct means
by which HIV may contribute to the development of AIDS-NHL.
In a recent study, we noted that elevated levels of AID expression
were seen in those HIV+ subjects who went on to develop NHL,
with the highest levels seen in those who developed Burkitt’s
lymphoma [17], a form of B cell NHL that is characterized by the
MYC:Ig chromosomal translocation, a result of AID activity
[35,36].
Our results also suggest that direct interactions between HIV-
encoded molecules, such as env protein, and receptors on human
B cells, are not responsible for HIV-mediated AID expression, as
CD40L-negative HIV preparations were not seen to induce AID
expression in agreement with the studies carried by Martin et al
[24]. This is in contrast to the results of studies by He, et al [23], in
which it was seen that HIV env had B cell-stimulatory effects.
These different results may be due, in part, to differences in the
source of HIV env, as He, et al used soluble envelope protein, while
we exposed B cells to infectious HIV preparations. Also, the B cell
preparations utilized in that study were different from those used
in the current study. It is important to note that the results
presented here do not exclude the potential role of other immune
stimulatory molecules of host origin that are incorporated into
HIV virions in the induction of AID expression by B cells, as it is
certainly possible that virion-associated host cell-encoded mole-
cules other than CD40L may be contributing to B cell activation.
Interestingly, other viruses (EBV, HCV) and microbes (H. pylorii)
are known to be able to induce AID expression, and are associated
with the development of B cell lymphoma [18,19,20,37]. In this
study, we found that exposure of B cells to HIV resulted in marked
AID expression by three days post-exposure, while exposure to
EBV required ten days for optimal AID expression [20]. This
difference in the kinetics of induction of AID expression by these
two viruses may be due to EBV having to infect B cells and express
viral proteins (i.e., LMP1) in order to induce AID expression, while
HIV may induce AID expression more quickly, because it does so
by direct CD40L:CD40 stimulation, which does not require viral
infection.
Finally, it is important to note that chronic antigenic and/or
cytokine-mediated stimulation of B cells, in the setting of HIV
infection-associated immune dysfunction, also would be expected
to result in AID expression. Therefore, the interaction of CD40L+
HIV virions with B cells is clearly not the only mechanism that has
the potential to induce aberrant AID expression, and contribute,
potentially, to the accumulation of molecular lesions that lead to
NHL. Clearly, further study is needed to determine the relative
contribution of virion-associated CD40L to the induction of B cell
activation and AID expression in HIV infected persons, as well as
to determine if other similar immune activation molecules
incorporated into HIV virions are active in inducing B cell
activation and AID gene expression and activity.
Materials and Methods
CD40L and T147N HIV
pCD40L (CD40L) and pT147N (CD40L mutant) was kindly
provided by R. Kornbluth (University of California San Diego).
pNL4-3 or pJR-CSF HIV molecular clones were obtained through
the AIDS Repository Reagent Program (Germantown, MD).
293T human embryonic kidney cells (ATCC CRL-11268) were
transfected with these HIV molecular clones [38]; these cells were
plated at 2610
5cells/well in 0.5 ml of RPMI with 1% glutamine in
a 24 well plate. For each well, 1 mg of pCD40L or pT147N and/or
0.5 mg of pNL4-3 or pJR-CSF was diluted in 50 ml of RPMI (for
co-transfections the total DNA was 1.5 mg) and 1.2 mlo f
lipofectamine in 50 ml of RPMI. Lipofectamine-DNA complexes
were incubated for 20 min at room temperature, added to wells
(100 ml per well) and incubated for 3 days at 37uC and 5% CO2.
Supernatants were collected after 3 days.
RNA isolation, Taqman RT-PCR
RNA isolation and PCR for AID were performed as previously
described [20]. Real time PCR measurements were done in
duplicate for the samples and in triplicate for the standard curve.
AID mRNA levels detected by quantitative TaqMan RT-PCR
were normalized for total RNA content by dividing the AID copy
number by the GAPDH copy number [20]. This AID/GAPDH
ratio was then multiplied by 10,000 to provide a relative numerical
index of AID expression that is adjusted for RNA content [(AID/
beads coated with anti-CD40L, followed by magnetic separation. RNA was then purified from the viruses bound to the beads, and were CD40L-
positive virions (CD40L(+)), as well as the viruses that did not bind to beads and were CD40L-negative virions (CD40L(2)), followed by Taqman RT-
PCR for viral RNA. Viral load, absolute CD4 number, percent CD4 cells (% CD4) and treatment status is listed for each subject, where available (n/a=
not available).
doi:10.1371/journal.pone.0011448.g002
AID Induced by CD40L+ HIV
PLoS ONE | www.plosone.org 5 July 2010 | Volume 5 | Issue 7 | e11448Figure 3. CD40L-expressing HIV, but not CD40L-negative HIV, induced AID expression in B cells. a) TaqMan RT-PCR was used to asses
the expression of AID in B cells that were exposed to mock supernatants of 293T cells, which were not transfected (MOCK) (negative control), or
exposed to an agonistic anti-CD40 antibody+IL-4 (anti-CD40+IL-4) (positive control), stimulatory anti-CD40 antibody alone (anti-CD40), CD40L-
negative HIV-containing supernatants produced by transfecting 293T cells with NL4-3 (NL4-3 CD40L(2)), CD40L-positive HIV-containing supernatants
of 293T cells co-transfected with NL4-3 and with CD40L (NL4-3 CD40L(+)) or CD40L mutant (NL4-3 CD40Lmut). B cells were also exposed to these
different NL4-3 preparations and cultured for 3 days. B cells exposed to CD40L-positive HIV were also treated with anti-CD40L. b) TaqMan RT-PCR was
used to asses the expression of AID in B cells that were exposed to supernatants of 293T cells that were not transfected with HIV (MOCK), stimulatory
anti-CD40 antibody + IL-4 (anti-CD40+IL-4) (positive control), CD40L-negative HIV-containing supernatants produced by transfecting 293T cells with
JR-CSF (JR-CSF CD40L(2)), CD40L-positive HIV containing supernatants of 293T cells co-transfected with HIV and with CD40L (JR-CSF CD40L(+)), or
CD40L mutant (JR-CSF CD40Lmut). B cells were exposed to these different JR-CSF preparations and cultured for 3 days.
doi:10.1371/journal.pone.0011448.g003
AID Induced by CD40L+ HIV
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when the numerical index was .2.0.
B cell isolation from PBMC
Peripheral blood mononuclear cells (PBMC), from healthy
anonymous donors, were obtained from the UCLA AIDS Institute
Virology Core laboratory. PBMC were counted and resuspended
at 25610
6 cells/ml in cold PBS containing 0.1% BSA and 2 mM
EDTA. 25 ml of CD19 immunobeads (Dynal Biotech, Invitrogen)
was added per 25610
6 cells and incubated at 2-8uC for 20 minutes
on a rotator. CD19+ cells (B cells) were isolated using a magnet,
and washed 26 with PBS containing 0.1% BSA and 2 mM
EDTA. Beads were eliminated by adding 100 ml of Detachabead
(DAB, Dynal Biotech, Invitrogen) per 1610
6cells in culture
medium, while incubating for 40 minutes on a rotator. Following
this, detached cells were washed two-three times with culture
medium, after which cells were pelleted.
Exposure of B cells to HIV preparations
B cells were incubated with different HIV preparations. 6610
6
B cells were exposed to 1 ml of HIV supernatant (100 ng of p24)
or Mock supernatant, which are supernatants collected from same
uninfected cell lines or PBMC where the virus was grown, for
3 hours. 2610
6 B cells were exposed with HIV expressing CD40L,
T147N mutant or not expressing CD40L at a concentration of
100 ng of p24 for 2 hours. Cells were then washed with culture
media and were incubated for 3 days at 1610
6 cells/ml in a 24 cell
well plate at 37uC, 5% CO2. In order to inhibit viral replication,
azidothymidine (AZT) was added at a concentration of 10 mMa t
the time of HIV exposure, and incubated with HIV for 2 hours,
then cells were washed and cultured for 3 days. To block
CD40:CD40L interaction, we added blocking anti-CD40L
(Ancell, Minnesota) at 0.1 mg/ml at the time of HIV exposures,
then cells were washed and incubated for 3 days.
Isolation of CD40L positive viruses
CD40L+ viruses were isolated from virus preparations by
affinity binding, using beads coated with anti-CD40L antibodies.
Briefly, this was done by washing sheep anti-mouse IgG Dynal
magnetic beads (Dynal Biotech, Invitrogen) with at least 1 ml
PBS/0.1% BSA, resuspending these to the original volume. 25 ml
of beads were used per 1 ng of p24 in the viral preparations (4 ng
of p24 per viral preparation). 1.5 mg of anti-CD40L (3 mlo f
0.5 mg/ml antibody) (BD Pharmingen, San Jose, CA) was added
per 25 ml of beads. Washed beads were incubated with anti-
CD40L for 30 min at 4uC. CD40L antibody-coated were then
washed with at least 1 ml PBS/0.1% BSA, and resuspended to
their original volume. Viral preparations containing 4 ng of p24
were brought to a volume of 1 ml with PBS/0.1% BSA, added to
the beads, and incubated for 20–30 min at 4uC with tilting. Beads
bound to CD40L+ virus were then washed 2 times by adding
1 ml of PBS/0.1% BSA, and put into contact with a magnet for 2
minutes. Both, the bead-bound and unbound viruses were
disrupted by adding Triton X (final concentration 0.5%), and
assayed for p24 content by ELISA (Perkin Elmer), to quantify
the amount of CD40L+ and CD40L-negative HIV in these
preparations.
1 ml of plasma for each subject was incubated with CD40L
labeled beads as described above, then virus bound to beads were
resuspended in RLT buffer (Qiagen) and RNA extraction was
performed as described in [20]. Virions in plasma were isolated by
diluting 1 ml of plasma to 5 ml of PBS, then centrifuged for 90
minutes at 40,000 rpm, then pellet was resuspended in RLT buffer
(Qiagen) and RNA extraction was performed as described in [20].
5 ml of RNA extracts were used for HIV RNA Taqman RT-PCR.
[39]
Measurement of AID protein by flow cytometry
Briefly, 1-2610
6 cells were washed with 3 ml of cold PBS, cells
were then fixed by adding formaldehyde to a final concentration of
1% and incubating 4uC for 30 minutes. Cells were then washed
with PBS/1%BSA by centrifugation at 400 g for 5 minutes. Cells
were then permeabilized by adding 1 ml of 0.2% Tween/PBS for
15 minutes at 37uC. After this, cells were washed with 3 ml of
PBS/1% BSA, centrifuged, then resuspended in 50 ml of human
AB serum and antibodies were then added: 10 ml of 1:100 dilution
of the rat-anti AID primary antibody (Cell Signaling) or rat IgG
(final concentration of 1.56 mg/ml) to the assay tubes and
incubated for 20 minutes at 4uC. Cells were then washed by
adding 3 ml PBS/1% BSA, followed by centrifugation. Cells were
resuspended in 50 ml of Human AB serum and secondary
antibody goat anti-rat Alexa FluorH 488 (Invitrogen) was added
at a 1:100 dilution, then incubated for 30 minutes at 4uC. Cells
were washed again with 3 ml PBS/5% BSA. Then, cells were
resuspended in 50 ml of Mouse IgG (Caltag) diluted 1:15 and
incubated for 10 min at 4uC. Subsequently, labeled antibodies
were added: 10 ml of CD10-PE-Cy7 (BD), 10 ml of CD71-PE (BD
Pharmingen) and 10 ml CD19-Cy7-PE (BD Pharmingen), incu-
bated for 20 minutes at 4uC, washed with 3 ml of PBS/1%BSA
and resuspended in 300 ml of PBS/1%BSA followed by analysis by
flow cytometry.
Plasma specimens
For the assessment of CD40L expression on virions from the
plasma of HIV-infected subjects, archival plasma specimens were
utilized. These specimens were collected from HIV+ and HIV-
negative subjects who were in the UCLA Center of the
Multicenter AIDS Cohort Study (MACS) or were patients in
UCLA clinics.
Quantification of cytokine levels by multiplexed
immunometric assay
Levels of human cytokines in the culture supernatants of HIV-
exposed B cells were quantified using a multiplexed (Luminex
platform) immunometric assay (MILLIPLEX xMAP High Sensi-
tivity Human Cytokine Panel, Millipore). This assay can
simultaneously measure levels of the following human cytokines:
GM-CSF, IFNc, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10,
IL-12 (p70), IL-13 and TNFa. Supernatant cytokine levels were
assessed in two independent experiments.
Supporting Information
Figure S1 Exposure of B cells to CD40L bearing HIVNL4-3
virions resulted in increased cytokine expression. Multiplexed
Figure 4. Exposure of B cells to CD40L bearing HIVNL4-3 virions resulted in AID protein expression. Flow cytometry for the detection of
intracellular AID protein was performed for B cells stimulated with anti-CD40+IL-4, Mock (HIV-negative), T147N (non-functional mutant CD40L) and
CD40L-expressing HIVNL4-3 supernatants. B cells (CD19+) expressing intracellular AID protein were gated and cell-surface expression of CD10 and
CD71 was assessed on these AID+ cells. The results of a representative experiment are shown in this figure.
doi:10.1371/journal.pone.0011448.g004
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Sensitivity Human Cytokine Panel, Millipore) were performed on
supernantants of B cells stimulated with anti-CD40L+IL-4, Mock
(HIV-negative), T147N (non-functional mutant of CD40L) and
CD40L-expressing HIVNL4-3. The results shown represent mean
cytokine levels, and standard error of the mean. The asterisk
indicates that supernatant levels of secreted IL-4 were not reliably
assessed, as exogenous IL-4 had been added to those cultures.
Found at: doi:10.1371/journal.pone.0011448.s001 (1.56 MB TIF)
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